Data Announced on the Estimated Economic Impact of Treating Myelosuppression for ES-SCLC
Two posters on the efficacy of trilaciclib for treating myelosuppression were presented at the Virtual International Society for Pharmacoeconomics and Outcomes Research 2021.
A pair of posters were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) focusing on the estimated economic impact of treating myelosuppression for patients with extensive-stage small cell lung cancer (ES-SCLC), according to the company responsible for the data, G1 Therapeutics, Inc.1
The first poster focused on the cost-benefit analysis of preventing chemotherapy-induced myelosuppression with trilaciclib (Cosela) for this cohort of patients. The second poster analyzed the trends in prevalence, treatment patterns, myelosuppression, and health care burden for patients with SCLC.
“Chemotherapy remains a cornerstone of treatment for SCLC, and chemotherapy-induced myelosuppression is a frequent complication that may manifest as neutropenia, anemia, and/or thrombocytopenia,” Marc Chioda, PharmD, Vice President of Medical Affairs at G1 and co-author of both posters, said in a press release.
In the first scientific poster, the investigative team concluded that a cost-benefit model estimating the economic value of trilaciclib incorporated prior to chemotherapy for patients with ES-SCLC shows that trilaciclib could be economically favorable to address the incidence of myelosuppression.2
The cost-benefit model estimated a potential cost savings per patient of $15,006 based on a projected reduction of myelosuppressive adverse effects (AEs) and the costs associated with them. Using trilaciclib prior to chemotherapy was associated with fewer myelosuppressive AEs, with 0.6 events observed in patients with trilaciclib compared with 2.7 events for patients with trilaciclib.
The second poster presented findings on the impact of treatment-induced myelosuppression for Medicare patients with SCLC. According to the Surveillance, Epidemiology, and End Results (SEER)–Medicare analysis, the reported data suggest that myelosuppression poses a substantial burden on the health care system.3
Some of the integral findings included nearly 75% of patients treated with chemotherapy experienced anemia during the study timeframe. More, AEs reported among the patient population treated with chemotherapy included neutropenia (45.2%) and thrombocytopenia (27.0%). Pancytopenia was observed in 24.4% of all patients included in the research.
“These analyses add to the data that help clarify the potential positive financial impact of Cosela usage and the projected real-world economic value of Cosela,” explained Chioda. “Together, these data suggest that use of Cosela should be a favorable economic strategy in the first line of therapy compared with standard care.”
Trilaciclib was previously approved by the FDA on February 12, 2021, for decreasing the incidence of chemotherapy-induced myelosuppression prior to a platinum/etoposide-containing regimen or topotecan-containing regimen to treat ES-SCLC.4
The most common AEs associated with trilaciclib, defined as occurring in greater than 10% of patients, include fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia.
Reference:
1. G1 therapeutics presents two posters at ISPOR describing the estimated economic impact of treating myelosuppression among patients with extensive-stage small cell lung cancer. News release. G1 Therapeutics. Published May 17, 2021. Accessed May 26, 2021. http://investor.g1therapeutics.com/news-releases/news-release-details/g1-therapeutics-presents-two-posters-ispor-describing-estimated
2. Deniz B, Onyekwere U, Moran D, et al. Cost-Benefit Analysis of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer. Presented at: International Society for Pharmacoeconomics and Outcomes Research; May 17-20, 2021. Virtual. Accessed May 27, 2021. https://bit.ly/2TeYQpC
3. Epstein R, Nelms J, Moran D, et al. Trends in Prevalence, Treatment Patterns, Myelosuppression, and Burden on the Health Care System Among Patients with Small Cell Lung Cancer: A SEER-Medicare Analysis. Presented at: International Society for Pharmacoeconomics and Outcomes Research; May 17-20, 2021. Virtual. Accessed May 27, 2021. https://bit.ly/2SwTPsb
4. FDA approves drug to reduce bone marrow suppression caused by chemotherapy. News release. February 12, 2021. Accessed February 12, 2021. https://bit.ly/34m1lZN
